Xolair Interventional Study in ASD Patients With Comorbid Atopy
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Following the publication of two case studies that reported behavioral benefit in ASD
patients treated with omalizumab, the investigators will conduct a pilot trial to test the
proof-of-concept efficacy of omalizumab in ASD patients with comorbid atopic disease.
Investigators will evaluate behavioral improvement using three questionnaires. Investigators
will also perform fMRI on all subjects and obtain serum samples for quantification of
immunological biomarkers. If the trial is conclusive, the investigators will conduct a
larger-scale, randomized-controlled trial to further understand the pathology of allergy in
this subpopulation of ASD patients and the efficacy of this intervention.